# Tensha Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tensha-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.tenshatherapeutics.com
- Total disclosed funding: $0.5M
- Latest round: Series A (Jul 28, 2011)
- Investors on record: 1

## About

Tensha Therapeutics is focused on developing innovative cancer therapies, specifically targeting BET inhibitors for advanced treatment options in oncology.Tensha Therapeutics specializes in advancing cancer therapies. The firm is headquartered in Cambridge, US. In January 2016, Roche acquired Tensha Therapeutics for USD 115 mn, emphasizing its commitment to exploring BET inhibitors as a key therapeutic target. The CEO, James Oliviero, leads the company in its mission to enhance cancer treatment efficacy.Tensha Therapeutics develops innovative healthcare solutions in the oncology sector, particularly in cancer treatment. Their core focus involves the development of BET inhibitors, which are part of a new class of cancer therapies aimed at improving outcomes for patients with various types of cancers. The company's products are utilized by healthcare professionals across multiple global markets, emphasizing tailored solutions for healthcare providers.Tensha Therapeutics generates revenue through the direct sales of its cancer therapies to healthcare institutions and providers. Partnerships with larger healthcare organizations and distribution agreements expand its reach in the market. The company's innovative approach in developing therapies like BET inhibitors supports its revenue generation strategy, making advanced treatments more accessible to patients.Following the acquisition by Roche in January 2016, Tensha Therapeutics aims to utilize the USD 115 mn funding to advance its research on innovative cancer therapies, focusing on the development of BET inhibitors. The company plans to expand its product offerings and is targeting new markets to increase its presence in Europe and Asia-Pacific by 2025. The funding will support continued research and development efforts to bring new treatments to patients within these regions.

## Funding rounds

- Series A, Jul 28, 2011, $0.5M — HealthCare Ventures

## Investors

- HealthCare Ventures — Series A